A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves

Trial Profile

A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Rivaroxaban (Primary) ; Warfarin
  • Indications Atrial fibrillation; Valvular heart disorders
  • Focus Therapeutic Use
  • Acronyms RIVER
  • Most Recent Events

    • 07 Apr 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018 as reported by ClinicalTrials.gov.
    • 07 Apr 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 06 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top